Democratic Republic of the Congo & Serum Institute of India

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an outbreak of Ebola Bundibugyo, with 282 confirmed cases and 42 deaths, making it the primary location for vaccine development and trials.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an ongoing outbreak of the Bundibugyo strain of Ebola, leading to the World Health Organization's recommendations for experimental treatments and vaccines.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.